<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99104">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01862458</url>
  </required_header>
  <id_info>
    <org_study_id>12120552</org_study_id>
    <secondary_id>12120552</secondary_id>
    <nct_id>NCT01862458</nct_id>
  </id_info>
  <brief_title>Empyema Treated With tPA &amp; DNAse</brief_title>
  <official_title>Prospective Randomized Trial: Fibrinolysis With tPA (Tissue Plasminogen Activator) Versus tPA and DNAse in Children With Empyema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Mercy Hospital Kansas City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Mercy Hospital Kansas City</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to scientifically evaluate a new substrate for fibrinolysis
      compared to our standard tPA.

      The hypothesis, driven by a recent prospective trial, is that tPA may benefit from the
      addition of DNAse.

      The primary outcome variable between the two techniques will be length of hospitalization
      after initiation of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Length of stay</measure>
    <time_frame>3 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Empyema</condition>
  <arm_group>
    <arm_group_label>tPA alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tPA alone used to treat empyema</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tPA plus dornase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tPA plus dornase used to treat empyema</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tPA alone</intervention_name>
    <arm_group_label>tPA alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tPA plus dornase</intervention_name>
    <arm_group_label>tPA plus dornase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients less than 18 years of age requiring an intervention for empyema by one of the
        following:

          -  Septation or loculation seen on ultrasound or computed tomography or

          -  Greater than 10,000 white blood cells identified on pleural tap

        Exclusion Criteria:

          -  Immunodeficiency process

          -  Secondary diagnosis or condition that will keep them in the hospital beyond the
             empyema

          -  Existing contraindications to chest tube

          -  Documented allergy to one of the study medications
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shawn D St. Peter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Mercy Hospital and Clinics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shawn D St. Peter, MD</last_name>
    <phone>816-983-6465</phone>
    <email>sspeter@cmh.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan W Sharp, PhD</last_name>
    <phone>816-983-6670</phone>
    <email>swsharp@cmh.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shawn D St. Peter, MD</last_name>
      <phone>816-983-6465</phone>
      <email>sspeter@cmh.edu</email>
    </contact>
    <contact_backup>
      <last_name>Susan W Sharp, PhD</last_name>
      <phone>816-983-6670</phone>
      <email>swsharp@cmh.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Shawn D St. Peter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 22, 2013</lastchanged_date>
  <firstreceived_date>May 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Mercy Hospital Kansas City</investigator_affiliation>
    <investigator_full_name>Shawn St. Peter</investigator_full_name>
    <investigator_title>Assoc Prof</investigator_title>
  </responsible_party>
  <keyword>empyema</keyword>
  <keyword>tPA</keyword>
  <keyword>dornase</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Empyema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
